News
At the risk of stating the obvious, when evaluating a new EDC, step one is ensuring the EDC is in fact better. EDC technology ...
The single-inhaler demonstrated a meaningful improvement in lung function in the Phase III KALOS and LOGOS studies.
New long-term extension data from the Phase IIb/III QUASAR trial demonstrate that Tremfya (guselkumab) maintains durable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results